- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- January 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- May 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,208GBP
- Report
- December 2024
- 515 Pages
Global
From €3277EUR$3,600USD£2,783GBP
- Report
- February 2024
- 93 Pages
Asia Pacific
From €2685EUR$2,950USD£2,281GBP
- Report
- January 2024
- 127 Pages
Europe
From €2685EUR$2,950USD£2,281GBP
- Report
- December 2023
- 110 Pages
Europe
From €1342EUR$1,475USD£1,140GBP
€2685EUR$2,950USD£2,281GBP
- Report
- December 2023
- 116 Pages
Asia Pacific
From €1115EUR$1,225USD£947GBP
€2230EUR$2,450USD£1,894GBP
- Report
- October 2023
- 207 Pages
India
From €1798EUR$1,975USD£1,527GBP
€3595EUR$3,950USD£3,054GBP
- Report
- July 2023
- 284 Pages
Global
From €2503EUR$2,750USD£2,126GBP
€5006EUR$5,500USD£4,252GBP
- Report
- July 2023
- 227 Pages
Global
From €2503EUR$2,750USD£2,126GBP
€5006EUR$5,500USD£4,252GBP
- Report
- December 2023
- 192 Pages
Global
From €4232EUR$4,650USD£3,595GBP
- Report
- February 2024
- 186 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- October 2023
- 177 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- October 2023
- 174 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- February 2024
- 115 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 120 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 120 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- October 2023
- 150 Pages
Global
From €4414EUR$4,850USD£3,749GBP
- Report
- April 2024
- 140 Pages
Global
From €4504EUR$4,949USD£3,826GBP

The Syndromic Multiplex Diagnostic market is a subset of the Diagnostics industry that focuses on the development and commercialization of multiplex assays. These assays are used to detect multiple biomarkers from a single sample, allowing for the simultaneous diagnosis of multiple diseases or conditions. Multiplex assays are used in a variety of clinical settings, including infectious disease, oncology, and autoimmune disease.
The Syndromic Multiplex Diagnostic market is driven by the increasing demand for rapid and accurate diagnosis of multiple diseases. This demand is driven by the need for improved patient outcomes, cost savings, and the ability to diagnose multiple diseases in a single test.
Some companies in the Syndromic Multiplex Diagnostic market include Abbott, Bio-Rad, Cepheid, Luminex, and Qiagen. Show Less Read more